Review paper
Post-natalizumab disease reactivation in multiple sclerosis: systematic review and meta-analysis
Abstract
Natalizumab (NTZ) is sometimes discontinued in patients with multiple sclerosis, mainly due to concerns about the risk of progressive multifocal leukoencephalopathy. However, NTZ interruption may result in recrudescence of disease activity.The objective of this study was to summarize the available evidence about NTZ discontinuation and to identify which patients will experience post-NTZ disease reactivation through meta-analysis of existing...
Paper Details
Title
Post-natalizumab disease reactivation in multiple sclerosis: systematic review and meta-analysis
Published Date
Jan 1, 2019
Volume
12